Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients

被引:13
作者
Furer, Victoria [1 ,2 ]
Hazan, Eyal [3 ]
Mor, Adi [4 ]
Segal, Michal [4 ]
Katav, Avi [4 ]
Aloush, Valerie [1 ,2 ]
Elkayam, Ori [1 ,2 ]
George, Jacob [4 ,5 ]
Ablin, Jacob N. [3 ]
机构
[1] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[4] ChemomAb Ltd, Tel Aviv, Israel
[5] Kaplan Med Ctr, Rehovot, Israel
关键词
CHRONIC INFLAMMATION; CC-CHEMOKINE; CHRONIC PAIN; EOSINOPHIL; ARTHRITIS; RECEPTOR; MCP-1; IL-8; GLIA;
D O I
10.1155/2018/7257681
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
FMS patients demonstrate an altered profile of chemokines relative to healthy controls (HC). Eotaxin-2 is a potent chemoattractant distributed in a variety of tissues. The aim of the study was to compare serum levels of eotaxin-2 between FMS patients and HC and to examine a potential correlation between eotaxin-2 levels and clinical parameters of FMS. Methods. 50 patients with FMS and 15 HC were recruited. Data on the severity of FMS symptoms and depression were collected. Serum levels of eotaxin-2 (ELISA) were determined in all participants. High-sensitive CRP (hs-CRP) was measured in the FMS group. Results. The FMS cohort included predominantly females (84%), mean age of 49, and mean disease duration of 6 years. FMS patients exhibited significantly higher eotaxin-2 levels (pg/ml) versus HC: 833 (+384) versus 622 (+149), p = 0.04. Mean hs-CRP level among FMS patients was 4.8 + 6 mg/l, a value not indicative of acute inflammation. No correlation was found between eotaxin-2 and hs-CRP levels. No correlation was found between eotaxin-2 and severity measures of FMS or depression. Conclusion. Eotaxin-2 does not appear to be a candidate for a disease activity biomarker in FMS. Further research is warranted into the role of this chemokine in the pathophysiology of the FMS.
引用
收藏
页数:4
相关论文
共 24 条
[1]   Protective effect of eotaxin-2 inhibition in adjuvant-induced arthritis [J].
Ablin, J. N. ;
Entin-Meer, M. ;
Aloush, V. ;
Oren, S. ;
Elkayam, O. ;
George, J. ;
Barshack, I. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2010, 161 (02) :276-283
[2]   From airway inflammation to inflammatory bowel disease: Eotaxin-1, a key regulator of intestinal inflammation [J].
Adar, Tomer ;
Shteingart, Shimon ;
Ben Ya'acov, Anni ;
Shitrit, Ariella Bar-Gil ;
Goldin, Eran .
CLINICAL IMMUNOLOGY, 2014, 153 (01) :199-208
[3]   MCP-1 and IL-8 as Pain Biomarkers in Fibromyalgia: A Pilot Study [J].
Ang, Dennis C. ;
Moore, Michele N. ;
Hilligoss, Janna ;
Tabbey, Rebeka .
PAIN MEDICINE, 2011, 12 (08) :1154-1161
[4]  
Bazzichi L, 2007, CLIN EXP RHEUMATOL, V25, P225
[5]   Inflammatory/Stress Feedback Dysregulation in Women with Fibromyalgia [J].
Bote, Maria E. ;
Garcia, Juan J. ;
Hinchado, Maria D. ;
Ortega, Eduardo .
NEUROIMMUNOMODULATION, 2012, 19 (06) :343-351
[6]   Fibromyalgia A Clinical Review [J].
Clauw, Daniel J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (15) :1547-1555
[7]   Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes [J].
Forssmann, U ;
Uguccioni, M ;
Loetscher, P ;
Dahinden, CA ;
Langen, H ;
Thelen, M ;
Baggiolini, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (12) :2171-2176
[8]   Altered profile of chemokines in fibromyalgia patients [J].
Garcia, Juan J. ;
Cidoncha, Antonio ;
Bote, Maria E. ;
Hinchado, Maria D. ;
Ortega, Eduardo .
ANNALS OF CLINICAL BIOCHEMISTRY, 2014, 51 (05) :576-581
[9]   Elevated serum monocyte chemoattractant protein-4 and chronic inflammation in overweight subjects [J].
Hashimoto, Izumi ;
Wada, Jun ;
Hida, Aya ;
Baba, Masako ;
Miyatake, Nobuyuki ;
Eguchi, Jun ;
Shikata, Kenichi ;
Makino, Hirofumi .
OBESITY, 2006, 14 (05) :799-811
[10]   An emerging role for eotaxins in neurodegenerative disease [J].
Huber, Amanda K. ;
Giles, David A. ;
Segal, Benjamin M. ;
Irani, David N. .
CLINICAL IMMUNOLOGY, 2018, 189 :29-33